Study Contact

CONTACT

Lead Sponsor

Johnson & Johnson Enterprise Innovation Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
•Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
•Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
•Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
•Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

•Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
•Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
•Another concurrent or prior primary malignancy within the last 36 months at informed consent
•Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
•History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

Related studies

NCT06855771 · Carcinoma, Non-Small-Cell Lung

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

NCT06120140 · Carcinoma, Non-Small-Cell Lung

NCT04165798 · Carcinoma, Non-Small-Cell Lung

NCT06875310 · Carcinoma, Non-Small-Cell Lung

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)